cas 1151802-23-1|| where to buy 4-Bromo-1-cyclopropyl-1H-pyrazole

Product Name:4-Bromo-1-cyclopropyl-1H-pyrazole

IUPAC Name:4-bromo-1-cyclopropyl-1H-pyrazole

Packing Unit	Available Stock	Price($)
CM187743-1g	in stock	Ȁƞ
CM187743-5g	in stock	Ƅźź
CM187743-10g	in stock	źƞň
CM187743-25g	in stock	Ȁșƞ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:1151802-23-1; Molecular Formula:C6H7BrN2; Melting Point:-; Smiles Code:BrC1=CN(N=C1)C1CC1; Density:

: Catalog Number:CM187743; Molecular Weight:187.04; Boiling Point:; MDL No:MFCD18250639; Storage:Store at 2-8°C.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Cyclopropanes; Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.

: Vebreltinib; Avistone announced that they received conditional approval from the National Medical Products Administration (NMPA) to commercialize Vebreltinib (Bozitinib) to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in China. The conditional approval was based on results from a pivotal Phase II KUNPENG study with an objective response rate (ORR) of 75.0% and median progression-free survival (PFS) in patients with advanced METex14 mutations to 14.1 months with a good safety profile as was recently presented at the 2023 European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain. Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-Met Tyrosine Kinase Inhibitor (TKI).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.